Menu
Not yet recruiting NCT07497542

Normal Saline Infusion After Intravenous Thrombolysis in Stroke

Phase III Interventional Brain Infarction

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: normal saline, normal saline.
Who it may be relevant to
Registry conditions: Brain Infarction. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Safety and Efficacy of Immediate Abundant Intravenous Normal Saline Infusion for Stroke After Intravenous Thrombolysis: a Multi-centre Randomized Controlled Phase III Trial

Overview

The intravenous administration of abundant normal saline is an easy-to-use strategy commonly employed to expand the blood volume. This study aimed to evaluate the efficacy and safety of the early administration of an abundant normal saline infusion after intravenous thrombolysis for promoting functional independence in patients with acute ischemic stroke. This multicenter, randomized, phase III clinical trial intends to enroll stroke participants who have undergone intravenous thrombolysis. Eligible patients are randomized to receive either abundant intravenous normal saline infusion (2,000-2,500 mL; normal saline group) or a small volume of intravenous normal saline infusion (≤600 mL; control group) immediately after thrombolysis. The primary outcome is the comparison of the ordinal modified Rankin Scale score at 90 days (±3) after randomization between the treatment groups.

Interventions

  • Drug normal saline
    The participants will undergo 2,000-2,500 mL normal saline intravenous infusion immediately after intravenous thrombolysis.
  • Drug normal saline
    The participants will receive ≤600 mL of normal saline infusion after intravenous thrombolysis.

Primary outcome measures

  • The modified Rankin Scale distribution [Time frame: 90 days (±3)]

Eligibility criteria

Inclusion criteria

  • Age 18 to 80 years.
  • Acute ischemic stroke treated with intravenous thrombolysis.
  • Prestroke mordified Rankin Scale score ≤1;
  • Admission NIHSS score 4-25, with NIHSS 4-5 requiring the presence of a disabling deficit as defined in the 2026 AHA/ASA Guideline for the Early Management of Patients With Acute Ischemic Stroke.
  • Onset-to-needle time≤4.5 hours or DWI-FLAIR mismatch (guided by MRI evaluation) for patients with uncertain stroke onset time according to the inclusion criteria of the WAKE-UP study.
  • Signed informed consent.

Exclusion criteria

  • Contraindications to intravenous thrombolysis.
  • Planned endovascular treatment prior to enrollment.
  • History of heart failure, or pre-enrollment brain natriuretic peptide (BNP) ≥100 pg/mL, or clinical presentations or signs suggestive of heart failure.
  • History of atrial fibrillation, or pre-enrollment electrocardiogram indicating atrial fibrillation.
  • History of valvular heart disease or valve replacement surgery, suggesting cardioembolic stroke.
  • History of renal dysfunction, or pre-enrollment serum creatinine >133 μmol/L, or estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m².
  • Severe hemorrhage prior to enrollment, including symptomatic intracranial hemorrhage, gastrointestinal bleeding, respiratory tract bleeding, or massive skin and mucous membrane bleeding.
  • Premature termination of intravenous thrombolysis due to any reason, such as hemorrhage, allergic reaction, or seizure.
  • Participation in another clinical trial within the previous 3 months.
  • Poor compliance, or inability to adhere to the trial protocol or complete follow-up.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Treatment

Study locations

China · 1 center
  • Tianjin Medical University General Hospital — Tianjin

Identifiers

NCT: NCT07497542 · NS-STROKE-2

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗